Yuexin Yu

Yuexin is Director at Andera Partners. He has been involved in life sciences portfolio companies including Amolyt (acquired by AZ), ReViral (acquired by Pfizer), LogicBio (acquired by Alexion), Mineralys (MLYS), Artios, Evommune, Tubulis, TargED and JenaValve. Before joining Andera, Yuexin worked at 3H Health Investment where he led the investments of InnoCare (HK.9969, SH.688428), KeyMed (HK.2162), RareStone, EdiGen, and participated in the investments of CanSino (HK.6185), HeMo Bioengineering, and Imperative Care. Prior to that, Yuexin was in the life cycle management team of Remicade and Keytruda at Merck. Yuexin started his career as venture analyst at Mérieux Développement. Yuexin received BSc in Pharmacy at SJTU and MSc in Management at HEC Paris.